XIAP and melanoma: Disease stabilizations and even partial responses have already been observed in clinical trials (TL32711: CRC and melanoma, LCL161: objective responses with combinational therapy only) [24] As observed by other groups [42, 43], cIAP was also downregulated at low nanomolar doses in our experiments and accompanied by downregulation of XIAP in 3 out of 6 cell lines.